[JTc prolongation in hypertrophic cardiomyopathy amd arterial hypertension]

Daiva Emilija Rekiene1

  • 1Kauno medicinos universiteto Kardiologijos institutas, Sukileliu 17, 3007 Kaunas.

Insights

Transesophageal pacing of the left atrium detects pathological long JTc intervals in patients with hypertrophic cardiomyopathy and arterial hypertension, even when resting ECGs appear normal. This method aids in identifying sudden death risk factors.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Sudden Cardiac Death Research

Background:

  • Pathological prolongation of QTc and JTc intervals is a significant risk factor for sudden cardiac death.
  • Electrocardiogram (ECG) investigations, particularly during stress or pacing, can reveal critical cardiac information.

Purpose of the Study:

  • To identify factors contributing to sudden death in patients with hypertrophic cardiomyopathy (HCM) and arterial hypertension (AH).
  • To evaluate electrocardiographic changes, specifically JTc interval variations, using transesophageal pacing of the left atrium (TPL A) in these patient groups and healthy individuals.

Main Methods:

  • Transesophageal pacing of the left atrium was performed on 12 healthy individuals, 12 patients with arterial hypertension, and 13 patients with hypertrophic cardiomyopathy.
  • Pacing was conducted at three different rates (80, 100, and 130 bpm) for 3 minutes each.

Main Results:

  • No JTc interval prolongation was observed in the control group.
  • JTc interval prolongation ( > 0.35 s) was detected in 3 patients with arterial hypertension and 3 patients with hypertrophic cardiomyopathy during pacing.
  • Prior to pacing, prolonged JTc intervals at rest were noted in 5 hypertrophic cardiomyopathy patients and 1 arterial hypertension patient.

Conclusions:

  • Transesophageal pacing of the left atrium is effective in uncovering pathological long JTc intervals in patients with arterial hypertension and hypertrophic cardiomyopathy.
  • This pacing method can identify individuals at risk for sudden death when their resting electrocardiograms do not show JTc interval prolongation.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...